Newbridge Financial Services Group’s Dianthus Therapeutics DNTH Stock Holding History

Newbridge Financial Services Group’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$528	Buy	+6	New	+$623	﹤0.01%	1163

Other funds holding DNTH

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Newbridge Financial Services Group's DNTH Position: Q3 2026 in Review

Newbridge Financial Services Group opened a new position in Dianthus Therapeutics (DNTH) in Q3 2026: 6 shares worth $528. The stake represents ﹤0.01% of the portfolio and ranks #1163 among its holdings.

77 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

Newbridge Financial Services Group held 6 shares of Dianthus Therapeutics worth $528 as of Q3 2026.
Dianthus Therapeutics was a new Newbridge Financial Services Group position in Q3 2026.
Dianthus Therapeutics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q3 2026, its #1163 holding.
77 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Newbridge Financial Services Group's 13F filing for Q3 2026, filed 15 Oct 2026.